Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.
暂无分享，去创建一个
K. Brown | K. Flaherty | Y. Inoue | L. Richeldi | A. Wells | W. Wuyts | M. Kolb | B. Crestani | R. Schlenker‐Herceg | A. Devaraj | S. Stowasser | T. Moua | M. Quaresma | R. Goeldner | Y. Inoue